10-Q: LataMed AI Corp. Faces Financial Hurdles in Q2 2026

LataMed AI Corp. reported no revenue and significant operating losses for the six months ended June 30, 2026, raising substantial doubt about its ability to continue as a going concern.

Summary

• LataMed AI Corp. (formerly Catalyst Crew Technologies Corp.) reported no revenue for the three and six months ended June 30, 2026.
• Operating expenses increased to $77,045 for the three months and $120,429 for the six months ended June 30, 2026, primarily due to higher professional fees.
• Net loss for the three months ended June 30, 2026, was $87,408, compared to $29,182 in the prior year period.
• Net loss for the six months ended June 30, 2026, was $140,221, compared to $53,637 in the prior year period.
• The company has a working capital deficit of $771,081 as of June 30, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to accumulated deficits and reliance on future financing.
• The company is executing a strategy to develop an AI-enabled digital healthcare platform focused on Latin America, including clinical decision support, telehealth, and patient engagement technologies.
• The company completed its corporate rebranding to LataMed AI Corp. in April 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a very negative filing due to the company's continued lack of revenue, significant operating losses, and substantial doubt about its ability to continue as a going concern, despite a strategic pivot.

Positives

• The company is actively pursuing a new strategic direction with an AI-enabled digital healthcare platform for Latin America.
• Progress has been made in organizational development, technology integration, and regulatory planning for the new healthcare platform.
• The company completed its corporate rebranding to LataMed AI Corp., aligning its name with its new business focus.
• Management believes meaningful progress has been made toward establishing the operational and regulatory foundation for commercialization of its digital healthcare ecosystem.

Negatives

• No revenue was generated in the three or six months ended June 30, 2026.
• Operating expenses increased significantly, driven by professional fees.
• The company incurred substantial net losses of $87,408 for the quarter and $140,221 for the six months ended June 30, 2026.
• A working capital deficit of $771,081 exists as of June 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern.
• The company is entirely dependent on attracting and receiving funding from external sources.
• Disclosure controls and procedures were found to be not effective due to limited internal resources.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to significant accumulated losses and reliance on future financing.
• The company has no firm agreements for future financing and cannot assure that needed funds will be available on acceptable terms.
• Failure to obtain sufficient funding will restrict the company's ability to grow and may require suspension of operations.
• Any additional equity financing may involve substantial dilution to existing stockholders.
• The company's financial disclosure controls and procedures were not effective, increasing the risk of material misstatements.
• The company operates as one reportable segment, and the Chief Operating Decision Maker assesses performance on a consolidated basis, potentially obscuring segment-specific issues.

Future Outlook

The company is focused on developing an AI-enabled digital healthcare platform for Latin America, including clinical decision support, telehealth, and patient engagement technologies. Management believes meaningful progress has been made toward establishing the operational and regulatory foundation necessary for commercialization and intends to continue expanding its technology platform, pursuing strategic relationships, and advancing regulatory initiatives.

Management Comments

• Management believes meaningful progress has been made toward establishing the operational and regulatory foundation necessary for commercialization.
• The Company intends to continue expanding its technology platform, pursuing strategic relationships, and advancing regulatory initiatives as it works toward the commercial deployment of its digital healthcare ecosystem.
• Management concluded that the financial disclosure controls and procedures were not effective due to the Company's limited internal resources and lack of ability to have multiple levels of transaction review.

Industry Context

StockSavvy.ai notes that the digital healthcare and AI sectors are experiencing significant growth, particularly in emerging markets. However, LataMed AI Corp.'s lack of revenue and substantial losses place it at a very early and high-risk stage within this competitive landscape, requiring significant capital to achieve its ambitious goals.

Comparison to Industry Standards

• Companies in the digital health sector often focus on specific niches like telehealth, AI-driven diagnostics, or patient management platforms. LataMed AI Corp. aims for a broad ecosystem approach.
• Established players in AI and healthcare, such as Google Health, Microsoft Healthcare, and various telehealth providers, have significant R&D budgets and established market presence, which LataMed AI Corp. currently lacks.
• The path to commercialization in digital health typically involves extensive regulatory approvals, strategic partnerships, and significant user adoption, which are ongoing challenges for early-stage companies like LataMed AI Corp.

Legal Proceedings

• Management is currently not aware of any legal proceedings or claims that could have, individually or in the aggregate, a material adverse effect on the business, financial condition, or operating results.

Related Party Transactions

• As of June 30, 2026, and December 31, 2025, the company had notes due to a shareholder totaling $88,042, carrying a 10% interest rate and due upon demand.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity financing and the ongoing risk of the company's inability to continue as a going concern.
• Creditors and suppliers may face uncertainty regarding timely payment due to the company's precarious financial position and working capital deficit.
• Employees may experience job insecurity given the company's reliance on external funding and potential need to curtail operations.
• Potential customers and partners in the digital healthcare space may be hesitant to engage with a company facing significant financial challenges and lacking revenue.

Next Steps

• Continue executing the strategy of developing an AI-enabled digital healthcare platform focused on Latin America.
• Continue integration and evaluation of acquired intellectual property.
• Advance the company's organizational and operational infrastructure to support future commercialization.
• Continue development of the planned healthcare technology ecosystem.
• Continue regulatory planning, strategic partnership discussions, and business development initiatives.
• Evaluate opportunities to expand its presence into additional international healthcare markets.
• Continue expanding its technology platform, pursuing strategic relationships, and advancing regulatory initiatives.
• Seek additional financing in a private equity offering.

Key Dates

Recommendation

The company exhibits severe financial distress with no revenue, significant losses, a widening working capital deficit, and substantial doubt about its going concern status. Despite a strategic pivot towards digital healthcare, the lack of any commercial traction and the high dependence on uncertain future financing make it a high-risk investment.

Keywords

Digital Healthcare, Artificial Intelligence, Latin America, Healthcare Technology, Startup, Biotechnology, Fintech, Asset Purchase